Zurich (awp) – The American Medicines Agency (FDA) has approved a Roche screening test for type B lymphoma, making it possible to quickly diagnose this type of cancer, the Basel laboratory announced on Monday.
The US regulator has given the green light to the Ventana Kappa and Lambda Dual ISH in situ hybridization (ISH) diagnostic tool. The latter makes it possible to differentiate a type B tumor from a normal immune reaction against an infection, the pharmaceutical group detailed in a press release.
Type B lymphoma usually develops in the lymphatic system and accounts for approximately 85% of non-Hodgkin’s lymphoma (NHL). In the United States, it is one of the most common forms of cancer, accounting for 4% of all cancer cases. Around 80,000 people die from this disease each year across the Atlantic.
-al/ib
Swiss